Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma von Zakharia, Yousef, McWilliams, Robert, Shaheen, Monaster, Grossman, Kenneth, Drabick, Joseph, Milhem, Mohammed, Rixie, Olivier, Khleif, Samir, Lott, Ryan, Kennedy, Eugene, Munn, David, Vahanian, Nicholas, Link, Charles

Volltext

799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 6... von Fernandez-Penas, Pablo, Carlino, Matteo, Tsai, Katy, Atkinson, Victoria, Shaheen, Monaster, Sajeve, Thomas, Mihalcioiu, Catalin, Tom Van Hagen, Roberts-Thomson, Rachel, Haydon, Andrew, Mant, Andrew, Butler, Marcus, Daniels, Gregory, Buchbinder, Elizabeth, Hyngstrom, John, Moller, Mecker, Puzanov, Igor, Cowey, C Lance, Whitman, Eric, Ballesteros-Merino, Carmen, Jensen, Shawn, Fox, Bernard, Schmidt, Emmett, Krepler, Clemens, Diede, Scott, Browning, Erica, Hermiz, Reneta, Svenson, Lauren, Salazar, Jon, Lee, Jack, Baker, Christopher, Bannavong, Donna, Sell, Jendy, Kellie Malloy Foerter, Canton, David, Aung, Sandra, Twitty, Christopher, Algazi, Alain, Daud, Adil

Volltext